Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study

摘要: This study compares the safety profiles of pegylated interferon (PEG-IFN) α-2a and α-2b administered in combination with ribavirin, based on variable time to withdrawal from treatment due adverse events. We conducted a real-world retrospective cohort using Japanese database. Based eligibility criteria, individuals chronic hepatitis C virus (HCV) infection were identified database covering period December 2009 August 2015. The primary outcome measure was defined as difference events between patients receiving PEG-IFN combined ribavirin those ribavirin. analyzed multivariate Cox proportional hazards regression model. A frailty model also applied consider regional (prefectural) variation. After evaluation, 11058 included analysis. 3774 treated α-2a, 6764 α-2b, 11.84 12.30% respectively withdrawing showed no significant two groups (hazard ratio (HR), 95%CI; 0.918, 0.817 1.031; p=0.1475). results consistent even when variation other confounding variables adjusted In conclusion, there may be Applying method used here future studies novel regimens provide important information for HCV clinical practice.